SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Exelixis, Inc. and Sarepta Therapeutics, Inc., from 2014 to 2023.

Exelixis, Inc.: A Steady Climb

Exelixis has shown a consistent increase in SG&A expenses, starting at approximately $51 million in 2014 and reaching around $543 million by 2023. This represents a staggering 964% increase over the decade, reflecting the company's expansion and investment in administrative capabilities.

Sarepta Therapeutics, Inc.: A Competitive Edge

Sarepta's SG&A expenses also grew significantly, from about $49 million in 2014 to nearly $482 million in 2023, marking an 882% rise. This growth underscores Sarepta's strategic focus on scaling its operations to support its innovative therapies.

Both companies demonstrate a robust commitment to growth, with Exelixis slightly outpacing Sarepta in SG&A efficiency.